4536N Stock Chart & Stats
$250.00
$0.00(0.00%)
At close: 4:00 PM EDT
$250.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$250.00 - $250.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$68.53B
Enterprise Value$637.18B
Total Cash (Recent Filing)$78.26B
Total Debt (Recent Filing)$31.01B
Price to Earnings (P/E)15.0
Beta0.00
Next Earnings
Nov 05, 2026EPS Estimate
3.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)119.09
Shares Outstanding322,314,150
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.62
Price to Book (P/B)1.97
Price to Sales (P/S)2.01
P/FCF Ratio15.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)14.29
Revenue Forecast (FY)$35.95B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryThe strong recovery in profitability provides a more durable earnings base than the company had in 2023. Healthy operating and net margins, together with improved returns on equity, should support reinvestment, brand development, and resilience across the ophthalmology portfolio.
Conservative Balance SheetVery low leverage gives Santen substantial financial flexibility as it funds research, product lifecycle management, and international commercialization. A strong equity base also reduces dependence on borrowing and helps the company absorb earnings variability without excessive balance-sheet strain.
Positive Cash GenerationPositive operating and free cash flow demonstrate that Santen is converting a substantial portion of reported earnings into internally generated funds. This supports continued investment in ophthalmology products and provides capacity for capital allocation without relying heavily on external financing.
Bears Say
Weaker Cash ConversionThe gap between operating profit and cash generation indicates weaker cash conversion than ideal, while the decline from 2024–2025 suggests less consistent working-capital or earnings conversion. If sustained, this could constrain internally funded investment despite reported profitability.
Earnings VolatilityThe prior-year loss and weak operating margin show that Santen’s earnings trajectory has not been consistently stable. Such volatility makes forward profit generation less predictable and may limit management’s ability to plan investment, dividends, and product expansion with confidence.
Limited Balance-Sheet ExpansionA balance sheet that has not clearly expanded over time may indicate that the company is not consistently building its asset and equity base alongside operations. This could limit the scale of future investment and leaves less evidence of sustained capital accumulation.
Santen Pharmaceutical Co News
4536N FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was $250.00 and its highest was $250.00 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is $68.53B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported $2.668 earnings per share for the quarter, beating the consensus estimate of $2.535 by $0.133.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd does not currently pay dividends.
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate is 3.72.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,314,150 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of $2.668 in its last earnings report, beating expectations of $2.535. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in MX:4536N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
4536N Company Deck
4536N Earnings Call
Q1 2026
0:00 / 0:00